当前位置： SCI文献检索 > Alzheimers Research & Therapy期刊下所有文献 > Active immunotherapy options for Alzheimer's disease.

Active immunotherapy options for Alzheimer's disease.

Abstract：

:Alzheimer's disease (AD) is the most common cause of dementia and a major contributor to disability and dependency among older people. AD pathogenesis is associated with the accumulation of amyloid-beta protein (Aβ) and/or hyperphosphorylated tau protein in the brain. At present, current therapies provide temporary symptomatic benefit, but do not treat the underlying disease. Recent research has thus focused on investigating the molecular and cellular pathways and processes involved in AD pathogenesis to support the development of effective disease-modifying agents. In accordance with the existing Aβ-cascade hypothesis for AD pathogenesis, immunotherapy has been the most extensively studied approach in Aβ-targeted therapy. Both passive and active immunotherapies have been shown to effectively reduce Aβ accumulation and prevent downstream pathology in preclinical models. Following AN1792, second-generation active immunotherapies have shown promising results in terms of antibody response and safety. Comparatively, tau immunotherapy is not as advanced, but preclinical data support its development into clinical trials. Results from active amyloid-based immunotherapy studies in preclinical models indicate that intervention appears to be more effective in early stages of amyloid accumulation, highlighting the importance of diagnosing AD as early as possible and undertaking clinical trials at this stage. This strategy, combined with improving our understanding of the complex AD pathogenesis, is imperative to the successful development of these disease-modifying agents. This paper will review the active immunotherapies currently in development, including the benefits and challenges associated with this approach.

journal_name

Alzheimers Res Ther

journal_title

Alzheimer's research & therapy

authors

Winblad B,Graf A,Riviere ME,Andreasen N,Ryan JM

doi

10.1186/alzrt237

subject

Has Abstract

pub_date

2014-01-30 00:00:00

pages

7

issue

1

issn

1758-9193

pii

alzrt237

journal_volume

6

pub_type

杂志文章,评审

相关文献

Alzheimers Research & Therapy文献大全
  • Exploring the potential of the platelet membrane proteome as a source of peripheral biomarkers for Alzheimer's disease.

    abstract：INTRODUCTION:Peripheral biomarkers to diagnose Alzheimer's disease (AD) have not been established. Given parallels between neuron and platelet biology, we hypothesized platelet membrane-associated protein changes may differentiate patients clinically defined with probable AD from noncognitive impaired controls. METHOD...

    journal_title：Alzheimer's research & therapy

    pub_type： 杂志文章

    doi：10.1186/alzrt186

    authors： Donovan LE,Dammer EB,Duong DM,Hanfelt JJ,Levey AI,Seyfried NT,Lah JJ

    更新日期：2013-06-13 00:00:00

  • Statins and therapy of Alzheimer's disease: questions of efficacy versus trial design.

    abstract：:Recent trials of statins produced no benefit for subjects with Alzheimer's disease. These negative studies add to a growing list of negative clinical trials. These data point to a need for reevaluating the pathophysiology of late-onset Alzheimer's disease. Late-onset Alzheimer's disease might result from the cumulativ...

    journal_title：Alzheimer's research & therapy

    pub_type： 社论

    doi：10.1186/alzrt101

    authors： Wolozin B

    更新日期：2012-01-16 00:00:00

  • The relationship of weight change trajectory with medial temporal lobe atrophy in patients with mild Alzheimer's disease: results from a cohort study.

    abstract：INTRODUCTION:Weight loss has been described in 20% to 45% of patients with Alzheimer's disease (AD) and has been associated with adverse outcomes. Various mechanisms for weight loss in AD patients have been proposed, though none has been proven. This study aimed to elucidate a mechanism of weight loss in AD patients by...

    journal_title：Alzheimer's research & therapy

    pub_type： 杂志文章

    doi：10.1186/s13195-015-0098-1

    authors： Droogsma E,van Asselt D,Bieze H,Veeger N,De Deyn PP

    更新日期：2015-04-06 00:00:00

  • Kidney function and dementia risk in community-dwelling older adults: the Shanghai Aging Study.

    abstract：BACKGROUND:Association between kidney dysfunction and dementia has been studied in western cohorts, but with inconsistent conclusions which may be due to the different measurements of kidney function. We aim to verify the hypothesis that lower levels of kidney function would be associated with increased risk of inciden...

    journal_title：Alzheimer's research & therapy

    pub_type： 杂志文章

    doi：10.1186/s13195-020-00729-9

    authors： Wang M,Ding D,Zhao Q,Wu W,Xiao Z,Liang X,Luo J,Chen J

    更新日期：2021-01-11 00:00:00

  • An integrated multi-study analysis of intra-subject variability in cerebrospinal fluid amyloid-β concentrations collected by lumbar puncture and indwelling lumbar catheter.

    abstract：INTRODUCTION:Amyloid-β (Aβ) has been investigated as a diagnostic biomarker and therapeutic drug target. Recent studies found that cerebrospinal fluid (CSF) Aβ fluctuates over time, including as a diurnal pattern, and increases in absolute concentration with serial collection. It is currently unknown what effect differ...

    journal_title：Alzheimer's research & therapy

    pub_type： 临床试验,杂志文章

    doi：10.1186/s13195-015-0136-z

    authors： Lucey BP,Gonzales C,Das U,Li J,Siemers ER,Slemmon JR,Bateman RJ,Huang Y,Fox GB,Claassen JA,Slats D,Verbeek MM,Tong G,Soares H,Savage MJ,Kennedy M,Forman M,Sjögren M,Margolin R,Chen X,Farlow MR,Dean RA,Waring J

    更新日期：2015-07-29 00:00:00

  • The Third French Alzheimer Plan: analysis of the influence of a national public health initiative on scientific research productivity and impact.

    abstract：INTRODUCTION:The Third National Alzheimer Plan (2008-2012) was a major public health initiative in France that included €200 million of funding for research in Alzheimer disease and related disorders (AD). The aim of this study was to document trends in French academic output in AD following the implementation of the p...

    journal_title：Alzheimer's research & therapy

    pub_type： 杂志文章

    doi：10.1186/s13195-015-0144-z

    authors： Haeffner-Cavaillon N,Devos P,Ledoux S,Ménard J

    更新日期：2015-09-26 00:00:00

  • The association of APOE ε4 with cognitive function over the adult life course and incidence of dementia: 20 years follow-up of the Whitehall II study.

    abstract：BACKGROUND:Approximately 25% of the general population carries at least one ε4 allele of the Apolipoprotein E (APOE ε4), the strongest genetic risk factor for late onset Alzheimer's disease. Beyond its association with late-onset dementia, the association between APOE ε4 and change in cognition over the adult life cour...

    journal_title：Alzheimer's research & therapy

    pub_type： 杂志文章

    doi：10.1186/s13195-020-00740-0

    authors： Gharbi-Meliani A,Dugravot A,Sabia S,Regy M,Fayosse A,Schnitzler A,Kivimäki M,Singh-Manoux A,Dumurgier J

    更新日期：2021-01-04 00:00:00

  • The monoaminergic footprint of depression and psychosis in dementia with Lewy bodies compared to Alzheimer's disease.

    abstract：INTRODUCTION:Depression and psychosis are two of the most severe neuropsychiatric symptoms (NPS) in dementia with Lewy bodies (DLB) and Alzheimer's disease (AD). Both NPS have negative effects on cognitive performance and life expectancy. The current study aimed to investigate and compare monoaminergic etiologies betwe...

    journal_title：Alzheimer's research & therapy

    pub_type： 杂志文章

    doi：10.1186/s13195-014-0090-1

    authors： Vermeiren Y,Van Dam D,Aerts T,Engelborghs S,Martin JJ,De Deyn PP

    更新日期：2015-02-11 00:00:00

  • Human amyloid-β enriched extracts: evaluation of in vitro and in vivo internalization and molecular characterization.

    abstract：BACKGROUND:Intracerebral inoculation of extracts from post-mortem human Alzheimer's disease brains into mice produces a prion-like spreading effect of amyloid-β. The differences observed between these extracts and the synthetic peptide, in terms of amyloid-β internalization and seed and cell-to-cell transmission of cyt...

    journal_title：Alzheimer's research & therapy

    pub_type： 杂志文章

    doi：10.1186/s13195-019-0513-0

    authors： Pedrero-Prieto CM,Flores-Cuadrado A,Saiz-Sánchez D,Úbeda-Bañón I,Frontiñán-Rubio J,Alcaín FJ,Mateos-Hernández L,de la Fuente J,Durán-Prado M,Villar M,Martínez-Marcos A,Peinado JR

    更新日期：2019-06-29 00:00:00

  • Inflammation in the Alzheimer's disease cascade: culprit or innocent bystander?

    abstract：:The strongest known risk factors for late-onset Alzheimer disease (LOAD) remain a positive family history and the APOE epsilon4 allele. van Exel and colleagues used these known risk factors to identify high- and low-risk samples of middle-aged persons in whom they compared levels of inflammatory and vascular risk fact...

    journal_title：Alzheimer's research & therapy

    pub_type： 社论

    doi：10.1186/alzrt29

    authors： Tan ZS,Seshadri S

    更新日期：2010-04-12 00:00:00

  • Have we learnt all we need to know from genetic studies - is genetics over in Alzheimer's disease?

    abstract：BACKGROUND:Alzheimer's disease (AD) pathophysiology is mostly (>95%) not inherited in a Mendelian fashion. Such sporadic AD (sAD) forms do not exhibit familial aggregation and are characterized by complex genetic inheritance. Growing evidence indicates that multiple genes contribute to sAD-characteristic endophenotypes...

    journal_title：Alzheimer's research & therapy

    pub_type： 杂志文章

    doi：10.1186/alzrt165

    authors： Hampel H,Lista S

    更新日期：2013-03-18 00:00:00

  • Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer's Disease.

    abstract：:The cerebrospinal fluid (CSF) biochemical markers (biomarkers) Amyloidβ 42 (Aβ42), total Tau (T-tau) and Tau phosphorylated at threonine 181 (P-tau181) have proven diagnostic accuracy for mild cognitive impairment and dementia due to Alzheimer's Disease (AD). In an effort to improve the accuracy of an AD diagnosis, it...

    journal_title：Alzheimer's research & therapy

    pub_type： 杂志文章,评审

    doi：10.1186/s13195-019-0485-0

    authors： Hansson O,Lehmann S,Otto M,Zetterberg H,Lewczuk P

    更新日期：2019-04-22 00:00:00

  • Recommendations for cerebrospinal fluid collection for the analysis by ELISA of neurogranin trunc P75, α-synuclein, and total tau in combination with Aβ(1-42)/Aβ(1-40).

    abstract：BACKGROUND:The pathophysiology of neurodegeneration is complex. Its diagnosis requires an early identification of sequential changes in several hallmarks in the brains of affected subjects. The presence of brain pathology can be visualized in the cerebrospinal fluid (CSF) by protein profiling. It is clear that the fiel...

    journal_title：Alzheimer's research & therapy

    pub_type： 杂志文章

    doi：10.1186/s13195-017-0265-7

    authors： Vanderstichele H,Demeyer L,Janelidze S,Coart E,Stoops E,Mauroo K,Herbst V,François C,Hansson O

    更新日期：2017-06-06 00:00:00

  • Association of MAPT haplotypes with Alzheimer's disease risk and MAPT brain gene expression levels.

    abstract：INTRODUCTION:MAPT encodes for tau, the predominant component of neurofibrillary tangles that are neuropathological hallmarks of Alzheimer's disease (AD). Genetic association of MAPT variants with late-onset AD (LOAD) risk has been inconsistent, although insufficient power and incomplete assessment of MAPT haplotypes ma...

    journal_title：Alzheimer's research & therapy

    pub_type： 杂志文章

    doi：10.1186/alzrt268

    authors： Allen M,Kachadoorian M,Quicksall Z,Zou F,Chai HS,Younkin C,Crook JE,Pankratz VS,Carrasquillo MM,Krishnan S,Nguyen T,Ma L,Malphrus K,Lincoln S,Bisceglio G,Kolbert CP,Jen J,Mukherjee S,Kauwe JK,Crane PK,Haines JL,

    更新日期：2014-07-01 00:00:00

  • Safety and tolerability of BAN2401--a clinical study in Alzheimer's disease with a protofibril selective Aβ antibody.

    abstract：BACKGROUND:Several monoclonal antibodies for the treatment of Alzheimer's disease (AD) have been in development over the last decade. BAN2401 is a monoclonal antibody that selectively binds soluble amyloid β (Aβ) protofibrils. METHODS:Here we describe the first clinical study with BAN2401. Safety and tolerability were...

    journal_title：Alzheimer's research & therapy

    pub_type： 临床试验,杂志文章,多中心研究,随机对照试验

    doi：10.1186/s13195-016-0181-2

    authors： Logovinsky V,Satlin A,Lai R,Swanson C,Kaplow J,Osswald G,Basun H,Lannfelt L

    更新日期：2016-04-06 00:00:00

  • Systematic reviews on behavioural and psychological symptoms in the older or demented population.

    abstract：INTRODUCTION:Behavioural and psychological symptoms of dementia (BPS) include depressive symptoms, anxiety, apathy, sleep problems, irritability, psychosis, wandering, elation and agitation, and are common in the non-demented and demented population. METHODS:We have undertaken a systematic review of reviews to give a ...

    journal_title：Alzheimer's research & therapy

    pub_type： 杂志文章

    doi：10.1186/alzrt131

    authors： van der Linde RM,Stephan BC,Savva GM,Dening T,Brayne C

    更新日期：2012-07-11 00:00:00

  • Potential sources of interference on Abeta immunoassays in biological samples.

    abstract：:Therapeutic products that depend on the use of an in vitro diagnostic biomarker test to confirm their effectiveness are increasingly being developed. Use of biomarkers is particularly meaningful in the context of selecting the patient population where the therapeutic treatment is believed to be efficacious (patient en...

    journal_title：Alzheimer's research & therapy

    pub_type： 杂志文章,评审

    doi：10.1186/alzrt142

    authors： Vanderstichele H,Stoops E,Vanmechelen E,Jeromin A

    更新日期：2012-10-17 00:00:00

  • Cognitive composite score association with Alzheimer's disease plaque and tangle pathology.

    abstract：BACKGROUND:Cognitive composite scores are used as the primary outcome measures for Alzheimer's disease (AD) prevention trials; however, the extent to which these composite measures correlate with AD pathology has not been fully investigated. Since many on-going AD prevention studies are testing therapies that target ei...

    journal_title：Alzheimer's research & therapy

    pub_type： 杂志文章

    doi：10.1186/s13195-018-0401-z

    authors： Malek-Ahmadi M,Chen K,Perez SE,He A,Mufson EJ

    更新日期：2018-09-11 00:00:00

  • Challenges and opportunities for improving the landscape for Lewy body dementia clinical trials.

    abstract：:Lewy body dementia (LBD), including dementia with Lewy bodies and Parkinson's disease dementia, affects over a million people in the USA and has a substantial impact on patients, caregivers, and society. Symptomatic treatments for LBD, which can include cognitive, neuropsychiatric, autonomic, sleep, and motor features...

    journal_title：Alzheimer's research & therapy

    pub_type： 杂志文章,评审

    doi：10.1186/s13195-020-00703-5

    authors： Goldman JG,Forsberg LK,Boeve BF,Armstrong MJ,Irwin DJ,Ferman TJ,Galasko D,Galvin JE,Kaufer D,Leverenz J,Lippa CF,Marder K,Abler V,Biglan K,Irizarry M,Keller B,Munsie L,Nakagawa M,Taylor A,Graham T

    更新日期：2020-10-29 00:00:00

  • Diverse therapeutic targets and biomarkers for Alzheimer's disease and related dementias: report on the Alzheimer's Drug Discovery Foundation 2012 International Conference on Alzheimer's Drug Discovery.

    abstract：:The Alzheimer's Drug Discovery Foundation's 13th International Conference on Alzheimer's Drug Discovery was held on 10-11 September 2012 in Jersey City, NJ, USA. This meeting report provides an overview of Alzheimer's Drug Discovery Foundation-funded programs, ranging from novel biomarkers to accelerate clinical devel...

    journal_title：Alzheimer's research & therapy

    pub_type： 杂志文章

    doi：10.1186/alzrt159

    authors： Lane RF,Dacks PA,Shineman DW,Fillit HM

    更新日期：2013-02-04 00:00:00

  • The dynamics of monocytes and microglia in Alzheimer's disease.

    abstract：:Alzheimer's disease (AD) is the most common neurodegenerative disorder affecting older people worldwide. It is a progressive disorder mainly characterized by the presence of amyloid-beta (Aβ) plaques and neurofibrillary tangles within the brain parenchyma. It is now well accepted that neuroinflammation constitutes an ...

    journal_title：Alzheimer's research & therapy

    pub_type： 杂志文章

    doi：10.1186/s13195-015-0125-2

    authors： Thériault P,ElAli A,Rivest S

    更新日期：2015-04-15 00:00:00

  • Study partners: essential collaborators in discovering treatments for Alzheimer's disease.

    abstract：BACKGROUND:Global leaders have set an ambitious goal of developing interventions to effectively treat or prevent Alzheimer's disease by 2025. CASE PRESENTATION:Achieving this goal will require clinical trials to test promising interventions, yet Alzheimer's researchers are confronting a clinical trial recruitment cris...

    journal_title：Alzheimer's research & therapy

    pub_type： 社论

    doi：10.1186/s13195-018-0425-4

    authors： Largent EA,Karlawish J,Grill JD

    更新日期：2018-09-27 00:00:00

  • A language-based sum score for the course and therapeutic intervention in primary progressive aphasia.

    abstract：BACKGROUND:With upcoming therapeutic interventions for patients with primary progressive aphasia (PPA), instruments for the follow-up of patients are needed to describe disease progression and to evaluate potential therapeutic effects. So far, volumetric brain changes have been proposed as clinical endpoints in the lit...

    journal_title：Alzheimer's research & therapy

    pub_type： 杂志文章

    doi：10.1186/s13195-018-0345-3

    authors： Semler E,Anderl-Straub S,Uttner I,Diehl-Schmid J,Danek A,Einsiedler B,Fassbender K,Fliessbach K,Huppertz HJ,Jahn H,Kornhuber J,Landwehrmeyer B,Lauer M,Muche R,Prudlo J,Schneider A,Schroeter ML,Ludolph AC,Otto M,FTLD

    更新日期：2018-04-25 00:00:00

  • ADAM10 plasma levels predict worsening in cognition of older adults: a 3-year follow-up study.

    abstract：BACKGROUND:Blood-based biomarkers for Alzheimer's disease (AD) are highly needed in clinic practice. So far, the gold standards for AD diagnosis are brain neuroimaging and beta-amyloid peptide, total tau, and phosphorylated tau in cerebrospinal fluid (CSF); however, they are not attractive for large-scale screening. Bl...

    journal_title：Alzheimer's research & therapy

    pub_type： 杂志文章

    doi：10.1186/s13195-020-00750-y

    authors： Oliveira Monteiro MPA,Salheb Oliveira DSM,Manzine PR,Crispim Nascimento CM,Dos Santos Orlandi AA,de Oliveira Gomes GA,Dos Santos Orlandi F,Zazzetta MS,Pott-Junior H,Cominetti MR

    更新日期：2021-01-08 00:00:00

  • Health-related quality of life in people with predementia Alzheimer's disease, mild cognitive impairment or dementia measured with preference-based instruments: a systematic literature review.

    abstract：BACKGROUND:Obtaining reliable estimates of the health-related quality of life (HR-QoL) of people with predementia Alzheimer's disease [AD] (preclinical or prodromal AD), mild cognitive impairment (MCI) and dementia is essential for economic evaluations of related health interventions. AIMS:To provide an overview of wh...

    journal_title：Alzheimer's research & therapy

    pub_type： 杂志文章,评审

    doi：10.1186/s13195-020-00723-1

    authors： Landeiro F,Mughal S,Walsh K,Nye E,Morton J,Williams H,Ghinai I,Castro Y,Leal J,Roberts N,Wace H,Handels R,Lecomte P,Gustavsson A,Roncancio-Diaz E,Belger M,Jhuti GS,Bouvy JC,Potashman MH,Tockhorn-Heidenreich A,Gray

    更新日期：2020-11-18 00:00:00

  • Functional connectivity in cognitive control networks mitigates the impact of white matter lesions in the elderly.

    abstract：BACKGROUND:Cerebrovascular pathology, quantified by white matter lesions (WML), is known to affect cognition in aging, and is associated with an increased risk of dementia. The present study aimed to investigate whether higher functional connectivity in cognitive control networks mitigates the detrimental effect of WML...

    journal_title：Alzheimer's research & therapy

    pub_type： 杂志文章

    doi：10.1186/s13195-018-0434-3

    authors： Benson G,Hildebrandt A,Lange C,Schwarz C,Köbe T,Sommer W,Flöel A,Wirth M

    更新日期：2018-10-27 00:00:00

  • HHV-6A infection induces amyloid-beta expression and activation of microglial cells.

    abstract：BACKGROUND:The control of viral infections in the brain involves the activation of microglial cells, the macrophages of the brain that are constantly surveying the central nervous system, and the production of amyloid-beta (Aβ) as an anti-microbial molecule. Recent findings suggest a possible implication of HHV-6A in A...

    journal_title：Alzheimer's research & therapy

    pub_type： 杂志文章

    doi：10.1186/s13195-019-0552-6

    authors： Bortolotti D,Gentili V,Rotola A,Caselli E,Rizzo R

    更新日期：2019-12-12 00:00:00

  • Alzheimer's disease drug-development pipeline: few candidates, frequent failures.

    abstract：INTRODUCTION:Alzheimer's disease (AD) is increasing in frequency as the global population ages. Five drugs are approved for treatment of AD, including four cholinesterase inhibitors and an N-methyl-D-aspartate (NMDA)-receptor antagonist. We have an urgent need to find new therapies for AD. METHODS:We examined Clinical...

    journal_title：Alzheimer's research & therapy

    pub_type： 杂志文章

    doi：10.1186/alzrt269

    authors： Cummings JL,Morstorf T,Zhong K

    更新日期：2014-07-03 00:00:00

  • Efficient clearance of Aβ protofibrils in AβPP-transgenic mice treated with a brain-penetrating bifunctional antibody.

    abstract：BACKGROUND:Amyloid-β (Aβ) immunotherapy is one of the most promising disease-modifying strategies for Alzheimer's disease (AD). Despite recent progress targeting aggregated forms of Aβ, low antibody brain penetrance remains a challenge. In the present study, we used transferrin receptor (TfR)-mediated transcytosis to f...

    journal_title：Alzheimer's research & therapy

    pub_type： 杂志文章

    doi：10.1186/s13195-018-0377-8

    authors： Syvänen S,Hultqvist G,Gustavsson T,Gumucio A,Laudon H,Söderberg L,Ingelsson M,Lannfelt L,Sehlin D

    更新日期：2018-05-24 00:00:00

  • Brain volumes and cortical thickness on MRI in the Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability (FINGER).

    abstract：BACKGROUND:The Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability (FINGER) was a multicenter randomized controlled trial that reported beneficial effects on cognition for a 2-year multimodal intervention (diet, exercise, cognitive training, vascular risk monitoring) versus control (gene...

    journal_title：Alzheimer's research & therapy

    pub_type： 杂志文章,多中心研究,随机对照试验

    doi：10.1186/s13195-019-0506-z

    authors： Stephen R,Liu Y,Ngandu T,Antikainen R,Hulkkonen J,Koikkalainen J,Kemppainen N,Lötjönen J,Levälahti E,Parkkola R,Pippola P,Rinne J,Strandberg T,Tuomilehto J,Vanninen R,Kivipelto M,Soininen H,Solomon A,FINGER study grou

    更新日期：2019-06-04 00:00:00